$ABCL News
Last published 2d ago
- 2d agoABCLAbCellera Biologics Inc. - Q3 2026 Earnings Results and Business Update - ABCELLERA BIOLOGICS INCEarnings Call TranscriptsGood afternoon, and welcome to Abcelera's Q3 2026 Business Update Conference Call. My name is Cara, and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we will host a
- 2d agoABCLAbCellera Biologics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2d agoABCLAbCellera Reports Q3 2026 Business ResultsBusiness WireVANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results
- 2w agoABCLAbCellera to Present at Upcoming Investor Conferences in November 2026Business WireAbCellera (NASDAQ:ABCL) announced that the Company will present at the following investor conferences: Stifel Healthcare Conference, November 11, 2026 Jefferies Global Healthcare Conference in London, November
- 3w agoHYFTAMDNVDAABSI+1AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.GlobeNewswireAUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of
- 1mo agoABCLAbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingBusiness WireAbCellera (NASDAQ:ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San
- 1mo agoABCLAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026Business WireAbCellera (NASDAQ:ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live
- 1mo agoHYFTABCLLLYTWST+1AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireTowards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound...
- 1mo agoABCLAbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026Business WireAbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026
- 2mo agoHYFTABCLABSILLY+1Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.GlobeNewswireNEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it
- 3mo agoABCLAbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsBusiness WireAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and,
- 3mo agoABCLAbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain
- 3mo agoSCKTABCLSLNNTHIThe Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major MilestonesGlobeNewswireDENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT)
- 3mo agoHYFTTEMSDGRABCL+1AI Found an Influenza Target That Survives Viral MutationGlobeNewswireAUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and
- 3mo agoABCLPhase 2 ABCL635 Top-Line Results - ABCELLERA BIOLOGICS INCEarnings Call TranscriptsGood afternoon, and welcome to the ABCL 635 Phase 2 Clinical Update. My name is Jonathan, and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we will host a question
- 3mo agoABCLAbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability ProfileBusiness WirePhase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose ABCL635 significantly improved sleep and patient global impression of
- 3mo agoABCLAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026Business WireManagement to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET AbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of
- 3mo agoABCLAbCellera Reports Q2 2026 Business ResultsBusiness WireAbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Last quarter we
- 3mo agoABCLVRTXAbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other ConditionsBusiness WireAbCellera (NASDAQ:ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune
- 3mo agoHYFTSDGRABCLRLAY+1An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the NumbersPR NewswireFor years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can talk...
- 3mo agoHYFTABSIABCLVKTX+1As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22PR NewswireEquity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical...
- 4mo agoABCLAbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026Business WireAbCellera (NASDAQ:ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A
- 4mo agoABCLAbCellera Appoints Dr. Lynn Seely to its Board of DirectorsBusiness WireAbCellera (NASDAQ:ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. "Dr. Seely is a respected executive leader with a proven track record of
- 4mo agoHYFTTEMABCLSDGR+1As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the DataPR NewswireUSA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting...
- 4mo agoABCLJAZZJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesBusiness WireThe collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop Jazz has the
- 4mo agoJAZZABCLJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license...
- 5mo agoABCLAbCellera Appoints Dr. Victor Sandor to its Board of DirectorsBusiness WireAbCellera (NASDAQ:ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. "Dr. Sandor is an experienced director and a distinguished medical oncologist
- 6mo agoABCL2026 GLOBAL HEALTHCARE CONFERENCE - ABCELLERA BIOLOGICS INCEarnings Call TranscriptsWell, good afternoon. Thank you for joining us on this here, our second day of Bank of America's annual healthcare conference in very toasty Las Vegas. I'm very happy to be joined here on stage with Carl Hansen with Abce
- 6mo agoABCLAbCellera Biologics Inc. - Q1 2026 Earnings Results and Business Update - ABCELLERA BIOLOGICS INCEarnings Call TranscriptsGood afternoon, and welcome to Abcelera's Q1 2026 Business Update Conference call. My name is Ben, and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, there will be a
- 6mo agoABCLAbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635Business WireABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. Ended Q1 2026 with total available liquidity
- 6mo agoABCLAbCellera to Present at Upcoming Investor Conferences in May and June 2026Business WireAbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026 Jefferies Global Healthcare Conference in New York,
- 6mo agoABCLAbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings CallBusiness WireAbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement
- 7mo agoABCLAbCellera to Report First Quarter 2026 Financial Results on May 11, 2026Business WireAbCellera (NASDAQ:ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live
- 8mo agoABCLAbCellera Biologics Inc. - FY 2025 Earnings Results and Business Update - ABCELLERA BIOLOGICS INCEarnings Call TranscriptsGood afternoon and welcome to Abcelera's full year 2025 Business Update conference call. My name is Chelsea and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we wil
- 8mo agoABCLAbCellera Reports Full Year 2025 Business ResultsBusiness WireAbCellera (NASDAQ:ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2025, AbCellera
- 9mo agoABCLAbCellera to Present at Upcoming Investor Conferences in March and April 2026Business WireAbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4, 2026 KeyBanc Capital Markets Healthcare Forum,
- 10mo agoABCLAbCellera and Bruker Reach Global Settlement of Patent LitigationBusiness WireAbCellera (NASDAQ:ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. As part of the
- 11mo agoABCLAbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026Business WireAbCellera (NASDAQ:ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast of the presentation may be accessed through a link
- 1y agoABCLAbCellera Appoints Dr. Stephen Quake to its Board of DirectorsBusiness WireAbCellera (NASDAQ:ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made
- 1y agoABCLAbCellera Reports Q3 2025 Business ResultsBusiness WireAbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "AbCellera successfully
- 1y agoABCLAbCellera to Participate at Upcoming Investor Conferences in November and December 2025Business WireAbCellera (NASDAQ:ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium, November 6, 2025 Stifel Healthcare Conference, November
- 1y agoABCLAbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025Business WireAbCellera (NASDAQ:
- 1y agoABCLAbCellera Appoints Dr. Sarah Noonberg as Chief Medical OfficerBusiness WireAbCellera (NASDAQ:ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of industry experience
- 1y agoABCLAbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575Business WireABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis AbCellera (NASDAQ:ABCL) today announced it has dosed the first participants
- 1y agoABCLAbCellera to Participate at Upcoming Investor Conferences in SeptemberBusiness WireAbCellera (NASDAQ:ABCL) today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference, September 3-5, 2025 Morgan Stanley Annual Global Healthcare
- 1y agoABCLAbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoABCLAbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor SymptomsBusiness WireAbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor
- 1y agoABCLAbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025Business WireAbCellera (NASDAQ:ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live
- 1y agoABCLAbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to MenopauseBusiness WireAbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial
- 1y agoABCLAbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal CircuitBusiness WireThe Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells AbCellera (NASDAQ:ABCL) today announced that the United States Court of